QPPV.COM KNOWLEDGE ASSESSMENT

Marstacimab: Classification, Mechanism, Haemophilia Use and Pharmacovigilance Knowledge Assessment

Test your understanding of the concepts covered by Marstacimab: Classification, Mechanism, Haemophilia Use and Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 What is the most appropriate central pharmacovigilance concept for marstacimab?

Assessing only whether factor levels increased Assessing the dynamic balance between bleeding control and thrombotic potential Treating every breakthrough bleed as proof of pharmacological failure Evaluating injection-site reactions independently from all other safety information

Question 2 of 10 A breakthrough bleed occurs in a patient receiving marstacimab. Which is the most appropriate initial pharmacovigilance interpretation?

It necessarily demonstrates loss of efficacy It should be assessed in context, including trauma, surgery, adherence, dosing interruption, inhibitor status and bleeding site It proves that the patient has developed anti-drug antibodies It should be ignored because prophylaxis prevents all bleeding

Question 3 of 10 What should an effective pharmacovigilance governance system demonstrate for marstacimab?

That bleeding, thrombosis and rescue treatment are processed as unrelated concepts That thrombotic events, breakthrough bleeding, rescue treatment and inhibitor status are linked during case processing and aggregate review That all regional procedures use identical indications without updates That only spontaneous reports without follow-up are accepted

Question 4 of 10 Why is inhibitor status important when assessing a patient with haemophilia receiving marstacimab?

It determines whether TFPI exists in the patient's plasma It can alter breakthrough-bleeding treatment options, historical exposure to bypassing agents and interpretation of the treatment strategy It eliminates the need to record adherence It determines the anatomical site of every bleed

Question 5 of 10 An emergency department is treating acute bleeding in a patient receiving marstacimab. What medication-safety control is most important?

Withhold all haemostatic treatment until a factor level is available Ensure the standing marstacimab regimen is visible so additional haemostatic therapy is selected with awareness of the existing rebalancing effect Assume the patient has no baseline haemostatic treatment Automatically administer the highest possible dose of multiple haemostatic agents

Question 6 of 10 According to the article, what was the key feature of the United States indication expansion described in June 2026?

Restriction to adults with haemophilia A without inhibitors Expansion to patients aged 6 years and older with haemophilia A or B, with or without inhibitors Expansion only for surgical prophylaxis Removal of haemophilia B from the indication

Question 7 of 10 Why should treatment persistence and breakthrough-bleed frequency be considered in benefit-risk review?

They provide context on continued use, effectiveness and possible emerging tolerability or efficacy concerns They replace the need to assess serious adverse events They determine whether every thrombosis is drug-related They are relevant only to commercial forecasting

Question 8 of 10 Which additional information is most important when following up a reported thrombosis in a marstacimab-treated patient?

Only the colour of the injection device Objective diagnostic confirmation, anatomical site, timing, haemostatic exposures and independent risk factors Only whether the patient reported pain The patient's historical factor VIII level without event details

Question 9 of 10 How should expected local injection-site reactions be distinguished from hypersensitivity in case processing?

All local reactions should be classified as systemic hypersensitivity Local erythema or pain should be distinguished from systemic reactions, with recurrence on re-exposure captured where available Only reactions requiring hospitalisation are clinically relevant Injection-site reactions should be assessed as evidence of treatment failure

Question 10 of 10 A patient has recurrent bleeding while receiving marstacimab, but several doses were delayed. What is the most appropriate conclusion?

The recurrence definitively establishes biological treatment failure Adherence and dosing interruption must be assessed before concluding that the drug has lost efficacy Delayed doses are irrelevant because the mechanism is non-factor based The patient must have developed a thrombotic event

Marstacimab: Classification, Mechanism, Haemophilia Use and Pharmacovigilance Knowledge Assessment

Cookie Settings